Literature DB >> 33537125

Age, neutrophil lymphocyte ratio, and radiographic assessment of the quantity of lung edema (RALE) score to predict in-hospital mortality in COVID-19 patients: a retrospective study.

Anggraini Dwi Sensusiati1,2,3, Muhammad Amin2,3,4, Nasronudin Nasronudin3,5, Alfian Nur Rosyid3,4, Nanda Aulya Ramadhan2,3, Rofida Lathifah6, Eva Puspitasari2, Ria Indah Wahyuningtyas2, Erika Soebakti1,3.   

Abstract

Background: Available data suggest that case fatality rate of COVID-19 patients in Surabaya is higher than global cases. Thus, it is important to identify risk factors to prevent the mortality. This study aimed to assess the factors associated with hospital mortality of COVID-19 patients, and develop a prediction score based on these findings.
Methods: We analyzed 111 patients, who were diagnosed with COVID-19 based on reverse-transcriptase polymerase chain reaction. The following patient characteristics were obtained from records: age, gender, type of symptoms, onset of symptoms, neutrophil lymphocyte ratio (NLR), absolute lymphocyte count, chest x-ray abnormalities, lung involvement, type of lesion, radiographic assessment of the quantity of lung edema (RALE) score, and mortality. Data were analyzed using SPSS 25.0. Results Multivariate analysis showed that age >50 years ( p=0.043), NLR score >5.8 ( p=0.016) and RALE score >2 ( p=0.002) can predict the mortality of COVID-19 patients in the hospital. ROC curve analysis of the score ability to predict mortality showed an area under the curve of 0.794. The cut-off point is 4.5, with a sensitivity of 96.7% and specificity of 49.4% to predict the mortality of COVID-19 patient in the hospital. Conclusions Age, NLR score and RALE score were associated with mortality of COVID-19 patients in the hospital and might be used as a predictor for mortality of COVID-19 patients in health care centre where radiologists are available. The prediction score may be useful for frontline physicians to effectively manage patients with a higher score to prevent mortality. Copyright:
© 2021 Sensusiati AD et al.

Entities:  

Keywords:  COVID-19 mortality; NLR; RALE Score

Year:  2020        PMID: 33537125      PMCID: PMC7836085.2          DOI: 10.12688/f1000research.26723.2

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  4 in total

1.  The Role of Simple Blood Tests and a Modified Chest X-Ray Scoring System in Assessing the Severity Disease and Mortality Risk in COVID-19 Patients in a Secondary Hospital, Indonesia.

Authors:  Soedarsono Soedarsono; Deri Yunita; Emma Ayu Lirani; Robitha Kartika Sari; Yoga Indrawan Pratama; Afifah Listiati; Bambang Supriyanto
Journal:  Int J Gen Med       Date:  2022-06-30

2.  Imaging-based indices combining disease severity and time from disease onset to predict COVID-19 mortality: A cohort study.

Authors:  Giulia Besutti; Olivera Djuric; Marta Ottone; Filippo Monelli; Patrizia Lazzari; Francesco Ascari; Guido Ligabue; Giovanni Guaraldi; Giuseppe Pezzuto; Petra Bechtold; Marco Massari; Ivana Lattuada; Francesco Luppi; Maria Giulia Galli; Pierpaolo Pattacini; Paolo Giorgi Rossi
Journal:  PLoS One       Date:  2022-06-16       Impact factor: 3.752

3.  The Prognostic Capacity of the Radiographic Assessment for Lung Edema Score in Patients With COVID-19 Acute Respiratory Distress Syndrome-An International Multicenter Observational Study.

Authors:  Christel M A Valk; Claudio Zimatore; Guido Mazzinari; Charalampos Pierrakos; Chaisith Sivakorn; Jutamas Dechsanga; Salvatore Grasso; Ludo Beenen; Lieuwe D J Bos; Frederique Paulus; Marcus J Schultz; Luigi Pisani
Journal:  Front Med (Lausanne)       Date:  2022-01-05

4.  Utility of a Pulmonary Oedema Score for Predicting the Need for Mechanical Ventilation in COVID-19 Patients in a General Hospital.

Authors:  Criseida Torres-Vargas; José Legorreta-Soberanis; Belén Madeline Sánchez-Gervacio; Pablo Alberto Fernández-López; Miguel Flores-Moreno; Víctor Manuel Alvarado-Castro; Sergio Paredes-Solís; Neil Andersson; Anne Cockcroft
Journal:  Arch Med Res       Date:  2022-03-22       Impact factor: 8.323

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.